RAC1 and cancer: To test if the Rac1 knockdown effects on proliferation are applicable to cancer stem cells marked by CD133, a BrdU incorporation assay was performed in which BrdU positive cells were gated in CD133+ or CD133− population of both scr and Rac1 shRNA treated cells.